ArticleThe Journal of clinical investigation2007
IL-6 involvement in epithelial cancers.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 2 syntheses or guidelines pooled it, 268 citations in OpenAlex.
- Potential noninvasive biomarkers for the malignant transformation of oral leukoplakia: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review.Clinical & experimental metastasis · 2019Pooled it
- Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.Cancer science · 2017Trial
- Lung cancer chemoprevention with celecoxib in former smokers.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Cell death & disease · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Research square · 2025Article
- Engineering a 3D wounded skin equivalent to study early inflammatory and regenerative responsesFrontiers in bioengineering and biotechnology · 2025Article
- Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer.Biomolecules · 2024Article
- IL-6 is associated with poor seizure control in low-grade glioma patients undergoing primary resection.iScience · 2024Article
- IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential.International journal of molecular sciences · 2024Review
- The modulation of immune cell death in connection to microRNAs and natural products.Frontiers in immunology · 2024Review
- Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6.Heliyon · 2023Article
- Upregulation of TLR5 indicates a favorable prognosis in prostate cancer.The Prostate · 2023Article
- Immune-Epithelial Cross Talk in Regeneration and Repair.Annual review of immunology · 2023Review
- T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt.PLoS neglected tropical diseases · 2023Article
- Trial watch: chemotherapy-induced immunogenic cell death in oncology.Oncoimmunology · 2023Review
- Evidence of a role for interleukin-6 in anoikis resistance in oral squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2022Article
- Investigating key cell types and molecules dynamics in PyMT mice model of breast cancer through a mathematical model.PLoS computational biology · 2022Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this issue of the JCI, two reports provide intriguing new information on the role of the inflammatory cytokine IL-6 in breast and lung cancer. The study by Sansone et al. implicates IL-6 in the instigation of malignant properties in breast cancer stem cells (see the related article beginning on page 3988). The study by Gao et al. identifies mutant variants of EGFR as inducers of IL-6 in lung adenocarcinomas (see the related article beginning on page 3846). These studies add to our understanding of potential roles for IL-6 in cancer and further motivate investigations of IL-6-targeted chemotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.